(S)-Rivastigmine-d6 tartrate

• CAT Number: S000538
• CAS Number: 194930-00-2
• Molecular Formula: C18H22D6N2O8
• Molecular Weight: 406.46
• Purity: ≥95%
• Target: Cholinesterase (ChE)
• IUPAC Name: [3-[(1S)-1-[bis(trideuteriomethyl)amino]ethyl]phenyl] N-ethyl-N-methylcarbamate;(2R,3R)-2,3-dihydroxybutanedioic acid
• InChI: InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m01/s1/i3D3,4D3
• InChIKey: GWHQHAUAXRMMOT-XVXYZIQCSA-N
• SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O

(S)-Rivastigmine-d6 tartrate（Cat No.:S000538） is a deuterated form of the (S)-enantiomer of rivastigmine tartrate, where six hydrogen atoms have been replaced with deuterium. Rivastigmine, marketed under names like Exelon, is used primarily to treat symptoms of Alzheimer’s and Parkinson’s diseases by inhibiting cholinesterase, thus enhancing cholinergic function. The deuterated version, (S)-rivastigmine-d6 tartrate, offers increased metabolic stability, which can be useful in extending the drug’s effective duration in the body and in conducting detailed pharmacokinetic studies. These properties aid in understanding drug metabolism and optimizing therapeutic efficacy, especially in neurodegenerative disorders.